ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "IL-23"

  • Abstract Number: 1014 • 2019 ACR/ARP Annual Meeting

    Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients

    Siba Raychaudhuri1 and Smritikana Raychaudhuri 2, 1UC Davis School of Medicine, Sacramento, CA, 2UC Davis School of Medicine, Davis, CA

    Background/Purpose: Here we hypothesized that (i) IL-23/IL-23R system more specifically the specific IL-23p19 subunit mediated signaling system regulates expansion/maintenance and functional maturation in respect to…
  • Abstract Number: 1777 • 2019 ACR/ARP Annual Meeting

    The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis

    Daniele Mauro1, Federica Macaluso 2, Alessandra Nerviani 3, Marie-Astrid Boutet 3, Aroldo Rizzo 4, Riccardo Alessandro 2, Giuliana Guggino 2, Costantino Pitzalis 3 and Francesco Ciccia 5, 1Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, England, United Kingdom, 2University of Palermo, Italy, Palermo, Italy, 3Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, 4Pathology Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy., Palermo, Italy, 5University of Campania L. Vanvitelli, Naples, Italy

    Background/Purpose: Interleukin 12 (IL-12) and 23 (IL-23) may play a pivotal role in the pathogenesis of inflammatory diseases, including Spondyloarthritis (SpA). In mice, the deubiquitinase…
  • Abstract Number: 62 • 2018 ACR/ARHP Annual Meeting

    CCR6+CD4+ T Cells Drive IL-23R Signaling-Dependent Progression of Antigen-Induced Arthritis

    W Razawy1, N Salioska2, P Asmawidjaja3, A Otten-Mus4, N Kops5, M Oukka6, V Kuchroo7 and Erik Lubberts3, 1Rheumatology and Immunology, Erasmus MC, Rotterdam, Netherlands, 2Rheumatology, Erasmus MC, Rotterdam, Netherlands, 3Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 4Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 5Orthopedics, Erasmus MC, Rotterdam, Netherlands, 6Pediatrics, Seattle Children's Research Institute, Seattle, WA, 7Center for Neurologic Diseases, Harvard Institute of Medicine, Boston, MA

    Background/Purpose: The IL-23/IL-17A immune pathway is important for the progression of T cell-mediated arthritis. However, it is not known where IL-23R+ T cells locate during…
  • Abstract Number: 143 • 2018 ACR/ARHP Annual Meeting

    Aquaporin 3 (AQP3) Protein Is Highly Expressed in Psoriatic Plaques and AQP3 Gene Expression Strongly Induced By IL-23 in CD4+ Th17 Cells

    Ananta Paine1, Maria de la Luz Garcia-Hernandez2, Benjamin D. Korman2, Judilyn Duculan3, Mayte Suarez-Farinas4, James G. Krueger3 and Christopher T. Ritchlin2, 1Department of Medicine, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, 2Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, 3Laboratory for Investigative Dermatology, Rockefeller University, New York City, New York, USA, New York City, NY, 4Icahn School of Medicine at Mount Sinai, New York City, New York, USA, New York City, NY

    Background/Purpose: Th17, a subset of CD4+ helper T cells, provides protection against pathogens and malignancies, but also promotes immune-mediated-inflammation in a range of disorders including…
  • Abstract Number: 989 • 2018 ACR/ARHP Annual Meeting

    Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis

    Qingxuan Song, Matthew Loza, Karen Leander, Brittney Scott, Patrick Branigan and Kristen Sweet, Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that binds to the p19 subunit of IL23. In a recent Phase 2 study, GUS demonstrated…
  • Abstract Number: 1028 • 2018 ACR/ARHP Annual Meeting

    An Entheseal Innate Immune Cell Biological Basis for Differential Efficacy of PDE4 and IL-23 Pathway Blockade between Psoriatic Disease and Rheumatoid Arthritis

    Charlie Bridgewood1, Richard Cuthbert1, Abdulla Watad2, Tobias Russell1, Timothy Palmer3, Robert Dunsmuir4, Almas Khan4, Abhay Rao4, Miriam Wittmann5 and Dennis McGonagle1, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Department of Internal Medicine 'B', Sheba Medical Center, Ramat Gan, Ramat Gan, Israel, 3School of Pharmacy and Medical Sciences, University of Bradford, Bradford, United Kingdom, 4Department of Spinal Surgery, National Health Service, Leeds, United Kingdom, 5NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Both IL-23 and phosphodiesterase (PDE) 4 inhibition are ineffective in RA but show efficacy in PsA-related synovitis despite similar cytokine and molecular profiles between…
  • Abstract Number: 2021 • 2018 ACR/ARHP Annual Meeting

    Th22 Cells in Peripheral Blood and Synovial Fluid of Patients with Enthesitis Related Arthritis

    Sandeep Kansurkar1, Ankita Singh2, Ramnath Misra3 and Amita Aggarwal3, 1Dept of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: IL-17 and IL-22 are important cytokines in pathogenesis of spondyloarthropathy. In an IL-23 or IL-22 over-expressing mouse model it was shown that enthesitis is…
  • Abstract Number: 2603 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders

    Jeffrey Crowley1, Kim A Papp2, Chih-ho Hong3, Jeff Parno4, Alan M Mendelsohn4, Qing Li5 and Nicole Cichanowitz5, 1Bakersfield Dermatology, Bakersfield, CA, 2Probity Medical Research, Waterloo, ON, Canada, 3University of British Columbia, Department of Dermatology and Skin Science and Probity Medical Research, Surrey, BC, Canada, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, 5Merck & Co., Inc., Kenilworth, NJ

    Background/Purpose: Etanercept (ETN), an anti-TNF medication, was among the first biologics approved for psoriasis. Additional psoriasis medications that have been developed, or are in development,…
  • Abstract Number: 2604 • 2018 ACR/ARHP Annual Meeting

    Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials

    Melinda Gooderham1, Boni E. Elewski2, David M. Pariser3, Howard Sofen4, Alan M Mendelsohn5, Nicole Cichanowitz6 and Qing Li6, 1Probity Medical Research, and Skin Center for Dermatololgy, Waterloo, and Peterborough, ON, Canada, 2University of Alabama at Birmingham, Birmingham, AL, 3Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, 4Ronald Reagan UCLA Medical Center, Department of Medicine (Dermatology) UCLA, Los Angeles, CA, 5Sun Pharmaceutical Industries, Inc., Princeton, NJ, 6Merck & Co., Inc., Kenilworth, NJ

    Background/Purpose: Tildrakizumab (TIL), a high-affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody, has demonstrated efficacy in the treatment of chronic plaque psoriasis.1,2 Here, we evaluate the…
  • Abstract Number: 2L • 2017 ACR/ARHP Annual Meeting

    Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis

    Philip J Mease1, Herbert Kellner2, Akimichi Morita3, Alan J. Kivitz4, Kim A. Papp5, Stella Aslanyan6, Beate Berner7, Kun Chen8, Ann Eldred8 and Frank Behrens9, 1Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 2Private Practice and Division of Rheumatology KHI Neuwittelsbach, München, Germany, 3Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 4Altoona Center for Clinical Research, Duncansville, PA, 5K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, 6Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 7Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 8AbbVie Inc., North Chicago, IL, 9CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany

    Background/Purpose: Interleukin-23 (IL-23), a key regulator of multiple effector cytokines (including IL-17, IL-22, and TNF), has been implicated in psoriatic lesions, synovitis, enthesitis, and bone…
  • Abstract Number: 660 • 2017 ACR/ARHP Annual Meeting

    Strain-Dependent IL-17A Secretion By CD4-CD8- DN αβ T Cells Correlates with Disease Susceptibility in Murine Spondyloarthritis

    Imtiyaz Hossain, Mederbek Matmusaev and Joerg Ermann, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Hydrodynamic injection of IL-23 minicircles into adult B10.RIII mice induces an inflammatory disease with phenotypic features of human spondyloarthritis. Tissue-resident CD4-CD8- double negative (DN)…
  • Abstract Number: 1576 • 2017 ACR/ARHP Annual Meeting

    IL-23 Promotes Fecal Microbiota Dysbiosis Associated with Susceptibility to Spondyloarthritis and Ileitis in ZAP-70 Mutant SKG Mice

    Linda Rehaume1, Nicholas Matigian1, Kate Ormerod2, Alicia Kang1, Richard Linedale1, Olga Zbarskaya1, Kristine Kikly3, Joshua Daly2, Nancy Lachner2, Philip Hugenholtz2, Mark Morrison1, Kim-Anh Lê Cao4 and Ranjeny Thomas1, 1The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, 2Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia, 3Biotechnology Discovery Research, Eli Lilly and Co, Indianapolis, IN, 4School of Mathematics and Statistics, Centre for Systems Genomics, The University of Melbourne, Melbourne, Australia

    Background/Purpose: Identification of disease-associated or protective bacteria may elucidate new biomarkers or probiotic supplements for people suffering from SpA, or for people at-risk of disease…
  • Abstract Number: 1578 • 2017 ACR/ARHP Annual Meeting

    The Initiation, but Not the Persistence, of Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats Is Crucially Dependent on the IL-23 Axis

    Melissa van Tok1,2, Songqing Na3, Joel Taurog4, Dominique Baeten2,5 and Leonie van Duivenvoorde1,2, 1Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Clinical Immunology and Rheumatology/Experimental immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 3Eli Lilly and Company, Indianapolis, IN, 4Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX, 5Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: IL-17A is a central driver of spondyloarthritis (SpA) pathology. IL-17A production was originally proposed to be IL-23 dependent. Emerging preclinical and clinical evidence from…
  • Abstract Number: 1581 • 2017 ACR/ARHP Annual Meeting

    Differential Involvement of Synovial and Entheseal Inflammation in Mediating Pathological IL23 Axis Signaling in Spondyloarthritis

    Ed Purdue1, Josselyn Galdamez1, Madeline Epsten2, Rima Abhyankar3, Kathleen Hoyt4, Michelle Lewis4, Devan Dove4, Jon Hill5, Alexander Klimowicz4, Gerald Nabozny6, Joseph Wahle4 and Lisa A. Mandl7, 1Research, Hospital for Special Surgery, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, New York, NY, 4Department of Immunology and respiratory discovery research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 5Department of Discovery research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 6[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 7Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY

    Background/Purpose: Although accumulating evidence continues to point toward a critical role for IL23 signaling in spondyloarthritis (SpA), the cellular and molecular events involved, as well…
  • Abstract Number: 1582 • 2017 ACR/ARHP Annual Meeting

    RORγt Inhibition Selectively Targets Pathogenic Subsets of Human iNKT and γδ-T Cells Enriched in Spondyloarthritis While Preserving Tissue Protective IL-22 Responses

    Koen Venken1,2, Mark Labadia3, Kathleen Hoyt3, Anita Wayne3, Robert Hughes3, Michael Turner3, Dustin Smith4, Christian Harcken4, Tine Decruy5,6, Joseph Wahle7, Chao-Ting Wang3, Peggy Jacques8, Sofie Van Gassen9, Gaëlle Varkas10, Heleen Cypers10, Filip van Den Bosch11, Yvan Saeys9, Gerald Nabozny12 and Dirk Elewaut13,14, 1Department of Rheumatology, Faculty of Medicine and Health Sciences, Laboratory for Molecular Immunology and Inflammation,, Ghent, Belgium, 2VIB Inflammation Research Center, Ghent University, Ghent, Belgium, 3Research and Development Boehringer-Ingelheim, Ridgefield, CT, 4Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 5Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium, Ghent, Belgium, 6VIB Inflammation Research Center, Ghent, Belgium, 7Department of Immunology and respiratory discovery research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 8Ghent University Hospital, Ghent, Belgium, 9Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium, 10Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, 11Rheumatology, Ghent University Hospital, Gent, Belgium, 12[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 13VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, 14Department of Rheumatology, Laboratory for molecular immunology and inflammation, Ghent, Belgium

    Background/Purpose: Dysregulated IL-23/IL-17 responses have been linked to a myriad of inflammatory diseases including psoriasis, psoriatic arthritis and other forms of spondyloarthritides (SpA). IL-23/IL-17 inflammation…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology